European CHMP recommends license extension of nivolumab (Opdivo) for treatment of oesophageal or gastro-oesophageal junction cancer
The license extension is as monotherapy for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.
Source:
European Medicines Agency